Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients

Official title

A Prospective, Open-label, Single-arm, Phase II Trial Investigating the Efficacy and Safety of Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients

Overview

The current standard of care for locally advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiation and consolidation immunotherapy. In real world clinical practice, patients who cannot tolerate concurrent chemoradiation generally received radiotherapy alone or sequential chemoradiation. These patients are more likely to develop distant metastases and therefore may require tolerable systemic consolidation regimens. However, there is a lack of evidence from clinical studies on consolidation immunotherapy after radiotherapy alone or sequential chemoradiation. The aim of the study is to explore the efficacy and safety of Tislelizumab consolidation therapy after radiotherapy or sequential chemoradiation in locally advanced NSCLC patients who are intolerable of concurrent concurrent chemoradiation.

Interventions

• Drug Tislelizumab
  Tislelizumab: 200mg d1,q21d\*17

Primary outcome measures

• Progression-free survival [Time frame: 6 months after enrollment]

Secondary outcome measures (3)

• Overall survival [Time frame: From date of enrollment to maximum of 3 years or death]
• Objective response rate [Time frame: From date of enrollment to maximum of 3 years or death]
• Treatment-related adverse events [Time frame: Duration of treatment and follow up until death or 3 years after enrollment]

Eligibility criteria

Inclusion criteria

• Patients with stage III(AJCC 8th) unresectable NSCLC, or resectable but intolerant or refusing surgery;
• Intolerable of concurrent chemoradiation;
• No progression after radiotherapy or sequential chemoradiation;
• Chemotherapy: standard dose of 2-6 cycles of paclitaxel, pemetrexed or gemcitabine in combination with platinum; Radiotherapy: starting within 3 months after chemotherapy using IMRT or VMAT technique. The target volume includes the primary tumor and regional lymph nodes, and the prescription dose 95% PTV ranges from 50Gy to 66Gy;
• ECOG PS0-2;
• PD-L1≥1%;
• Age≥18 years, and life expectancy>3 months;
• Adequate Hematologic, biochemistry and organ function (to be confirmed by test results within 7 days prior to the first dose);
• Be able to provide written informed consent (ICF) and able to understand and agree to comply with study requirements and assessment schedule.

Exclusion criteria

• Patients with EGFR-sensitive mutations and ALK rearrangements;
• Any prior use of anti-PD-1, anti-PD-L1, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibodies (including Ipilimumab or any other antibody targeting the T-cell co-stimulation or checkpoint pathway);
• History of allergy to components of Tislelizumab;
• Any active malignancy within 2 years prior to enrollment, except for the specific cancers examined in this study and any locally recurrent cancers that have been eradicated (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, cervical or breast cancer in situ);
• History of interstitial lung disease or pneumonia requiring oral or intravenous steroids;
• Progression after radiotherapy or sequential chemoradiation;
• Unresolved ≥grade2 toxicities from radiotherapy and sequential chemoradiation, (excluding those that the investigator determines do not affect study treatment, such as alopecia);
• Grade 2 or severe Pneumonia from radiotherapy or sequential chemoradiation;
• Administration of a live vaccine within 30 days prior to treatment start (seasonal influenza vaccine without live vaccine is allowed);
• Severe chronic or active infections (including tuberculosis infections, etc.) requiring systemic antibacterial, antifungal or antiviral therapy ≤ 14 days prior to treatment start;
• History of immunodeficiency, including a positive HIV test, or other acquired or congenital immunodeficiency disease, or a history of organ transplantation;
• History of active autoimmune disease requiring systemic therapy;
• Treatment with long-term systemic immunosuppressive medications (≥10 mg/d prednisone or equivalent doses of other steroids) or other immunosuppressive medications;
• History of uncontrolled cardiovascular disease; or clinically significant QT interval prolongation, or QTc interval >480 ms during screening period;
• Abnormal liver function \[total bilirubin > 1.5 times of the upper limit of normal value; ALT/AST > 2.5 times of the upper limit of normal value in patients without liver metastases and ALT/AST > 5 times of the upper limit of normal value in patients with liver metastases\], abnormal renal function (serum creatinine > 1.5 times of the upper limit of normal value);
• History of serious concomitant diseases (e.g., severe hypertension, diabetes, thyroid disease, active infection, etc.) ;
• History of diagnosed neurological or psychiatric disorders, including epilepsy or dementia;
• Unsuitable for participation in this study assessed by investigators;
• Patients who were already enrolled in other clinical studies;
• Mixed lung cancer with small cell components.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

China · 1 center

• Peking University Cancer Hospital and Institute — Beijing

Identifiers

NCT: NCT05758116 · 2022YJZ46

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗